2016 Annual Resu sults ts Midatech Pharma plc April 2017 - PowerPoint PPT Presentation

Mar 30, 2024 •460 likes •753 views

2016 Annual Resu sults ts Midatech Pharma plc April 2017 Disclaimer THIS PRESENTATION MAY NOT BE COPIED OR REPRODUCED IN ANY FORM, FURTHER DISTRIBUTED OR PASSED ON, DIRECTLY OR INDIRECTLY, TO ANY OTHER PERSON, OR PUBLISHED, IN WHOLE OR IN

2016 Annual Resu sults ts Midatech Pharma plc April 2017

Recommend

Ah Ahol old D d Del elha haize e Q2 2 2 201 019 re resu sults ts August 7, 2019 Hi

Ah Ahol old D d Del elha haize e Q2 2 2 201 019 re resu sults ts August 7, 2019 Hi High ghli ligh ghts ts Frans Muller President & CEO 2 Second d qu quar arter ter resu sults lts impa pacte cted d by by Stop p

334 views • 16 slides

Sec econ ond d Qua uarter er 20 2017 Re 7 Resu sults August 9, 2017 Q2 Q2 Hi High ghli

1 Sec econ ond d Qua uarter er 20 2017 Re 7 Resu sults August 9, 2017 Q2 Q2 Hi High ghli ligh ghts ts Dick Boer President and CEO 3 Second Quarte rter r 2017 7 Results sults Highlights second quarter 2017 Improved pro

296 views • 29 slides

2016 I 6 Interim R Resu sults P s Prese sentation Scott M McGr Greg egor, C Chi hief E

2016 I 6 Interim R Resu sults P s Prese sentation Scott M McGr Greg egor, C Chi hief E Exec ecutive e Officer er Scott L Lair ird, Fin inance D Dir irector 28 th September 2016 28 2016 H1 2016 Highlights Market seeding

449 views • 21 slides

2016 16 Hal alf-ye year ar resu sults lts presen sentat tation ion 19 May 2016 Andrew

2016 16 Hal alf-ye year ar resu sults lts presen sentat tation ion 19 May 2016 Andrew Rashbass, CEO Cont ntext xt Weak first half the run- off of operational deficit last year and first quarter of this combined with

764 views • 47 slides

Financial Resu Financial Resu lt Presentation lt Presentation November 1 2012 November 1,

For the Year ended S For the Year ended S September 30, 2012 September 30, 2012 p p , , Financial Resu Financial Resu lt Presentation lt Presentation November 1 2012 November 1, 2012 Securities Code : 9438 0 P2 Overview of Consol

506 views • 31 slides

R R R Resu Resu R esults esults l l f l l f ts f ts f for f for f or the year

R R R Resu Resu R esults esults l l f l l f ts f ts f for f for f or the year or the year h h year year en ended en ended d d d d d d d d d d 28 Marc 28 M 28 Marc 28 M 28 M 28 M 28 M 28 M arch 2009 arch

300 views • 16 slides

For personal use only Half Y Year Resu sults P Pres esen entation 1H FY FY19 28 February

For personal use only Half Y Year Resu sults P Pres esen entation 1H FY FY19 28 February 2019 | ASX:PGC 1H19 financial highlights For personal use only ~9% organic growth achieved in 1H19 from Continuing Revenue business (~2x

360 views • 19 slides

FULL FULL YEAR R RE RESU SULTS S 2019 2019 Joa Joachim im Dr rr (CE (CEO) Chr

J O S T W E R K E A G M A R C H 2 5 , 2 0 2 0 FULL FULL YEAR R RE RESU SULTS S 2019 2019 Joa Joachim im Dr rr (CE (CEO) Chr Chris istia ian Ter erli linde (CF (CFO) Disclaimer THIS PRESENTATION IS CONFIDENTIAL AND

589 views • 22 slides

RESU SULTS TS PRESE SENT NTATION ION WARSAW , 17 TH MAY 2018 Disclaimer This is pr

1Q18 1Q18 FINA FINANC NCIA IAL RESU SULTS TS PRESE SENT NTATION ION WARSAW , 17 TH MAY 2018 Disclaimer This is pr presentati tation (th (the Presentation) was pr prepar ared by by LPP SA SA (th (the Company) with ith

668 views • 49 slides

20 2019 Pr Prel eliminary Resu sults 27 th February 2020 1 Howdens 2019 Interim Results

20 2019 Pr Prel eliminary Resu sults 27 th February 2020 1 Howdens 2019 Interim Results Howdens 2019 Interim Results Andr ndrew ew L Livi ving ngston Chief Executive Officer 2 Howdens 2019 Interim Results Howdens 2019

824 views • 80 slides

Nexan Ne xans 20 2019 19 Fu Full ll Ye Year ar Re Resu sults lts th Februa Paris, s,

Nexan Ne xans 20 2019 19 Fu Full ll Ye Year ar Re Resu sults lts th Februa Paris, s, 20 th ruary ry 2020 Safe Harbor This presentation contains forward-looking statements which are subject to various expected or unexpected risks and

611 views • 39 slides

IN INTERI ERIM M RESU SULTS S PRESENT SENTATION TION 12 March ch 2020 20 0 Introduction

IN INTERI ERIM M RESU SULTS S PRESENT SENTATION TION 12 March ch 2020 20 0 Introduction Portfolio overview C O N T E N T S Valuation overview Liquidity analysis Brait transaction 1 Overview of the last six months and market

661 views • 27 slides

Thi hird d Qua uarter er 20 2018 Re 8 Resu sults November 7, 2018 Q3 Q3 Hi High ghli

Thi hird d Qua uarter er 20 2018 Re 8 Resu sults November 7, 2018 Q3 Q3 Hi High ghli ligh ghts ts Frans Muller President and CEO Highli hlights hts Third ird qu quar arter ter 2018 Strong sales and earnings growth,

398 views • 18 slides

APB M Methods a and Prelimi minary Rese search R Resu sults ts Mark Newton Lowry David

APB M Methods a and Prelimi minary Rese search R Resu sults ts Mark Newton Lowry David Hovde Zack Legge Pacific Economics Group Research, LLC Ontario Energy Board 29 October 2018 Toronto, ON 2 Overview ew Benchmarking Basics

762 views • 60 slides

Thi hird d Qua uarter er 20 2017 Re 7 Resu sults November 8, 2017 Q3 Q3 Hi High ghli

Thi hird d Qua uarter er 20 2017 Re 7 Resu sults November 8, 2017 Q3 Q3 Hi High ghli ligh ghts ts Dick Boer President and CEO 3 Third ird Quarte rter r 2017 7 Resul ults ts Highlights third quarter 2017 Pro forma net

403 views • 22 slides

FY FY19 R Resu sults P s Prese sentation Fo For the year ended 31 March 2019 an and Ou

FY FY19 R Resu sults P s Prese sentation Fo For the year ended 31 March 2019 an and Ou Outlo look for FY20 20 29 May 2019 PACIFIC EDGE IS IN A UNIQUE GLOBAL POSITION (PEB.NZX) First to market for 17 years: Four proprietary,

384 views • 26 slides

InnoCare Pharma 2019 Annual Report Presentation April 2020 Disclaimer These materials are for

InnoCare Pharma 2019 Annual Report Presentation April 2020 Disclaimer These materials are for information purposes only and do not constitute or form part of an offer or invitation to sell or issue or the solicitation of an offer or invitation to

727 views • 37 slides

COVID-19 and Celiac Disease Dr Donald Duerksen Chair Professional Advisory Committee Canadian

COVID-19 and Celiac Disease Dr Donald Duerksen Chair Professional Advisory Committee Canadian Celiac Association COVID-19 Canada April 27, 2020 COVID-19 Information Overload! COVID-19 is found in the stool There are ACE receptors

383 views • 15 slides

Ecology, Epidemiology, and Prevention of Lyme Disease in the United States Paul Mead, MD, MPH

Ecology, Epidemiology, and Prevention of Lyme Disease in the United States Paul Mead, MD, MPH Chief, Epidemiology and Surveillance Activity Division of Vector-Borne Diseases National Center for Emerging and Zoonotic Infectious Diseases Centers

770 views • 73 slides

XTL BIOPHARMACEUTICALS TO PRESENT AT BIOTECH SHOWCASE RAANANA, ISRAEL - (December 19, 2016) XTL

XTL BIOPHARMACEUTICALS TO PRESENT AT BIOTECH SHOWCASE RAANANA, ISRAEL - (December 19, 2016) XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ( XTL or the Company ), a clinical-stage biopharmaceutical company developing

297 views • 3 slides

Where we learn. There is no mold, -ACPS facilities Mold Inspection Network Lab Rating Scale

Where we learn. There is no mold, -ACPS facilities Mold Inspection Network Lab Rating Scale (Concentration of Spores) 0 1 2 3 4 5 No Species Found Scattered Very Low Low Medium High Nearly 60% of 7th grade classroom tested

325 views • 14 slides

Presentation of Diarrhoea Differential diagnosis of diarrhoea Infectious: o Viral

Presentation of Diarrhoea Differential diagnosis of diarrhoea Infectious: o Viral Norovirus; Rotavirus o Bacterial E.coli; Salmonella; Shigella; Campylobacter Vibrio cholerae C. difficile o Protozoal/parasites Giardia

458 views • 3 slides

NCI Experience Using Yeast brachyury Vaccine (GI 6301) in Patients with Advanced Chordoma

NCI Experience Using Yeast brachyury Vaccine (GI 6301) in Patients with Advanced Chordoma Christopher R. Heery, M.D. Laboratory of Tumor Immunology and Biology and Medical Oncology Branch National Cancer Institute, CCR, NCI, NIH

280 views • 25 slides

New Paradig Paradigms for Adv s for Advancing ncing Perso Personalized alized Medicine

1 2 New Paradig Paradigms for Adv s for Advancing ncing Perso Personalized alized Medicine Medicine 1 Pane Panelists lists Moderated by: Antoinette Konski Antoinette Konski, Partner, Foley & Lardner LLP Speakers: Anita Chawla,

352 views • 11 slides

More recommend

Explore More Topics

Stay informed with curated content and fresh updates.

animals pets art culture automotive transportation business finance computer internet construction architecture education-career electronics communication